Improved early diagnosis and determination of aggressiveness of prostate cancer (PC) is important to select suitable treatment options and to decrease over‐treatment. The conventional marker is total prostate specific antigen (PSA) levels in blood, but lacks specificity and ability to accurately discriminate indolent from aggressive disease.
In this study, we sought to identify a serum biomarker signature associated with metastatic PC. We measured 157 analytes in 363 serum samples from healthy subjects, patients with non‐metastatic PC and patients with metastatic PC, using a recombinant antibody microarray.
A signature consisting of 69 proteins differentiating metastatic PC patients from healthy controls was identified.
Conclusions and clinical relevance
The clinical value of this biomarker signature requires validation in larger independent patient cohorts before providing a new prospect for detection of metastatic PC.
- affinity proteomics
- antibody microarrays
- prostate cancer